The first biological inhibitor of hereditary angioedema, ruconest, approved by FDA
-
Last Update: 2014-07-18
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: biodicover 2014-7-18 on July 17, 2014, the US Food and Drug Administration (FDA) approved the first recombinant C1 esterase inhibitor, ruconest, a product for the treatment of hereditary angioedema in acute adult and adolescent patients Hereditary angioedema is an autosomal hereditary disease, which can occur at any age, but mostly in early adulthood The cause of the disease is the decrease of C1 lipase inhibitor (a kind of α 2 globulin) in the patients' serum or the functional defect, which leads to the over activation of C1, the uncontrolled cracking of C4 and C2, the increase of complement kallikrein, which leads to the increase of microvascular permeability and edema It affects between 6000 and 10000 people in the United States Ruconest is a recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema (HAE).
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
